Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2021

View Archived Issues

Enobosarm confers clinical benefit in patients with AR+/ER+ metastatic breast cancer

ChemoCentryx describes new PD-1/PD-L1 interaction inhibitors

Stanford University presents new anticancer peptides

New antibacterials discovered at Wockhardt

TroBio Therapeutics identifies new tropomyosin alpha-3 chain inhibitors

AAV9 encoding NPC intracellular cholesterol transporter 1 synthesized at StrideBio

TRPV1 antagonist SAF-312 reduces pain after photorefractive keratectomy

Natural language processing identifies impact of diazoxide choline on Prader-Willi syndrome

Anti-CD3 DARPin T-cell engager is active only in the tumor microenvironment

IMV to initiate phase Ib study of maveropepimut-S in breast cancer

Checkmate and Regeneron enter agreement to evaluate vidutolimod plus cemiplimab

Diffusion reports final data from phase Ib study of TSC in hospitalized COVID-19 patients

Key interim analysis findings from phase Ia/Ib monotherapy study of CUE-101 in HNSCC

G1 Therapeutics initiates phase II PRESERVE 4 study of trilaciclib in NSCLC

First patient dosed in phase I/II study of CBX-12 in advanced or metastatic refractory solid tumors

GBR-830 shows improvement at 16 weeks in patients with moderate to severe atopic dermatitis

Novel progression risk tissue markers in premalignant cervical lesions

Ascendis reports 58-week data from phase II OLE study of TransCon PTH in hypoparathyroidism

FDA authorizes Pfizer and BioNTech's COVID-19 vaccine for adolescents aged 12-15 years

Gavo-cel shows promising phase I/II results in patients with mesothelin-overexpressing solid tumors

Hamlet Pharma reports dose-escalation data on Alpha-1H in bladder cancer

Phase I trial of Ampion in long COVID receives IRB approval

Enrollment opens in phase II study of BA-3011 for metastatic NSCLC

New phase I trial evaluates PBCAR-19B in CD19-expressing malignancies

SARS-CoV-2 vaccines make progress in the young, the old, the in-between